Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Motor function restored in Parkinson’s mice with GT-02287
Parkinson’s News Today
Related Posts
Post navigation
Previous Post
UPDATE – Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Next Post
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
Latest Articles
Clear Filters
February 6, 2024
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Read More
April 24, 2024
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Read More
October 10, 2023
Dosing Underway for Phase 1 Parkinson Trial of GBA1-Targeting Agent GT-02287
Read More
Close
